Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

INTRODUCTION: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is diagnosed in approximately 15% of all human breast cancer (BrCa) patients. Currently, no targeted therapies exist for this subtype of BrCa and prognosis remains poor. Our laboratory has previously id...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Christina N, Tomlinson, Christine C, Michalowski, Aleksandra M, Chu, Isabel M, Luger, Dror, Mittereder, Lara R, Aprelikova, Olga, Shou, James, Piwinica-Worms, Helen, Caplen, Natasha J, Hollingshead, Melinda G, Green, Jeffrey E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680937/
https://www.ncbi.nlm.nih.gov/pubmed/22812567
http://dx.doi.org/10.1186/bcr3230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680937/
https://www.ncbi.nlm.nih.gov/pubmed/22812567
http://dx.doi.org/10.1186/bcr3230

Ejemplares similares